seed
Stage
1
Investors
About
Gila Therapeutics is a clinical-stage biotech company developing a topical lingual signaling platform that delivers micro-dose PYY and GLP-1 melts on the tongue to target brain regions regulating food intake and metabolism, aiming to treat obesity, type 2 diabetes, and cardiometabolic disorders without systemic exposure.
Explore Gila Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.